Vaginal Dryness and GSM: Causes, Symptoms, and Treatment Options

What Is Genitourinary Syndrome of Menopause?

GSM is a collection of genital, sexual, and urinary symptoms caused by estrogen deficiency. The 2014 consensus statement from the International Society for the Study of Women's Sexual Health and The Menopause Society replaced the older term "atrophic vaginitis" because that label captured only part of the picture. GSM affects the labia, clitoris, vaginal introitus, urethra, and bladder, not the vaginal canal alone.

The primary driver is the sharp decline in circulating estradiol that begins in perimenopause and continues after the final menstrual period. Estrogen receptors are densely expressed throughout the urogenital tract. When estradiol drops below roughly 50 pg/mL, the vaginal epithelium thins from its usual 15 to 20 cell layers to as few as 2 to 4 layers, collagen content falls, and glycogen stores diminish. Loss of glycogen starves the Lactobacillus colonies that normally keep vaginal pH between 3.8 and 4.5. Vaginal pH typically rises above 5.0 in women with GSM, increasing susceptibility to bacterial and yeast overgrowth [1].

Symptoms include vaginal dryness, burning, and irritation; pain during intercourse (dyspareunia); decreased lubrication with arousal; urinary urgency, frequency, and recurrent urinary tract infections. The VIVA (Vaginal Symptoms in Postmenopausal Women) survey of 3,520 women found that 55% reported moderate-to-severe vaginal symptoms, yet only 4% received prescription therapy [2]. That treatment gap is one of the most consistent findings in GSM research.

How GSM Differs From Other Perimenopause Symptoms

Hot flashes, night sweats, and mood disruption dominate early perimenopause, but they often improve as the body adapts to lower estrogen over 2 to 5 years. GSM works in the opposite direction. Without treatment, the condition progresses. The Menopause Society's 2023 position statement notes: "Genitourinary symptoms do not spontaneously resolve and tend to worsen with time in the absence of treatment." [3]

This distinction matters for clinical timing. A woman who tolerates vasomotor symptoms through lifestyle changes may still need targeted GSM therapy five years into postmenopause. Perimenopause itself, the window of irregular cycles averaging 4 to 8 years before the final period, can bring early vulvovaginal dryness even while systemic estrogen levels remain sporadically elevated. Tracking vaginal symptoms separately from hot flash severity gives a clearer therapeutic target.

Menopause insomnia adds a complicating layer. Fragmented sleep from night sweats reduces arousal and sexual interest, which can make GSM-related dyspareunia less noticeable until the patient attempts intercourse. A 2019 survey published in Menopause found that women with both insomnia and GSM reported significantly greater sexual distress scores than women with either condition alone [4]. Treating both simultaneously produces better patient-reported outcomes than addressing vasomotor symptoms in isolation.

Diagnosing GSM: What to Expect

Diagnosis is clinical and does not require a hormone blood panel in most cases. A provider examines the vulva and vagina for pallor, petechiae, loss of rugae, and introital narrowing. Vaginal pH above 4.6 measured with litmus paper supports the diagnosis. A vaginal maturation index, a Pap-smear-style slide counting parabasal, intermediate, and superficial cells, can quantify atrophy severity; a parabasal cell predominance above 5% is consistent with significant hypoestrogenism [5].

Serum FSH and estradiol levels are sometimes drawn to confirm menopausal status, but the American College of Obstetricians and Gynecologists (ACOG) notes that a single FSH measurement is insufficient for diagnosis in women still experiencing irregular periods [6]. The formal menopause diagnosis requires 12 consecutive months of amenorrhea in the absence of other causes, such as pregnancy, thyroid disease, or hyperprolactinemia. Thyroid dysfunction deserves specific mention: both hypothyroidism and hyperthyroidism can cause vaginal dryness, dyspareunia, and fatigue that overlap closely with GSM, so a TSH should be checked when the picture is unclear.

Vulvoscopy or biopsy is reserved for cases with visible lesions, suspicious pigmentation, or persistent symptoms that do not respond to standard estrogen therapy within 12 weeks.

First-Line Treatment: Local (Vaginal) Estradiol

Low-dose vaginal estradiol is the evidence-based first-line option for isolated GSM. It works by restoring estradiol locally without producing the systemic levels associated with oral estrogen. Four FDA-approved formulations cover most clinical scenarios.

Estradiol vaginal cream (Estrace, 0.01% estradiol): The standard initiation regimen is 2 g nightly for 2 weeks, then 1 g two to three times per week for maintenance. A 12-week randomized controlled trial (N=230) demonstrated a 75% reduction in the Most Bothersome Symptom score compared with 14% for placebo (P<0.001) [7].

Estradiol vaginal inserts / tablets (Vagifem, Yuvafem, 10 mcg): Inserted nightly for 2 weeks, then twice weekly. Serum estradiol rises by a mean of only 4 pg/mL above baseline at steady state, remaining well within the postmenopausal range. The REJOICE trial (N=764) showed statistically significant improvements in vaginal pH, maturation index, and patient-reported dyspareunia at 12 weeks versus placebo [8].

Estradiol vaginal ring (Estring, 7.5 mcg/day): Replaced every 90 days. Steady-state serum estradiol averages 8 pg/mL, making it an option for women who prefer a set-and-forget delivery method.

Prasterone (DHEA) vaginal insert (Intrarosa, 6.5 mg): Prasterone is an androgen precursor converted locally to estradiol and testosterone. The FDA approved it in 2016. In the AMELIA trial (N=216), nightly prasterone reduced dyspareunia severity by 1.42 points on a 0-to-3 scale compared with 0.97 for placebo (P<0.001) [9]. It offers a non-estrogen label for patients or prescribers hesitant to use estrogen terminology.

The Menopause Society states that low-dose vaginal estrogen is safe for the majority of women, including breast cancer survivors using aromatase inhibitors, pending oncologist input [3]. Systemic absorption at approved doses is minimal, and progestogen co-administration is not required for endometrial protection at these doses.

Second-Line and Non-Hormonal Options

Ospemifene (Osphena, 60 mg oral daily): This selective estrogen receptor modulator acts as an estrogen agonist in vaginal tissue and an antagonist in breast tissue. The FDA approved it in 2013 for moderate-to-severe dyspareunia due to GSM. Phase III data (N=826 to 12 weeks) showed a 3.8-fold increase in superficial cells, a 1.5 pH-unit decrease, and a 0.64-point reduction in Most Bothersome Symptom score versus placebo [10]. Hot flashes occurred in 7.3% of ospemifene users versus 2.6% placebo; it carries a class warning for venous thromboembolism similar to other SERMs.

Hyaluronic acid vaginal moisturizers: A 2021 Cochrane review found that hyaluronic acid moisturizer used three times weekly produced symptom relief comparable to low-dose vaginal estrogen over 8 weeks in women with mild-to-moderate GSM, though the quality of evidence was rated moderate [11]. These products (Revaree, Yes VM, Hyalo Gyn) are available without a prescription and are a reasonable starting point for women who decline hormonal options or as an adjunct to estrogen.

Silicone-based lubricants: Appropriate for symptom relief at the time of intercourse. They do not restore vaginal epithelium or normalize pH. Water-based lubricants with osmolality above 1,200 mOsm/kg may damage epithelial cells with repeated use; the WHO recommends lubricants below 380 mOsm/kg [12].

Laser therapy (fractional CO2, Er:YAG): The FDA issued a safety communication in 2018 warning that energy-based devices for vaginal rejuvenation have not been cleared for GSM and that adverse events including scarring and worsening pain have been reported. A 2021 randomized sham-controlled trial in JAMA (N=72) found fractional CO2 laser no better than sham for any GSM outcome at 12 months [13]. Current data do not support its routine use.

Systemic HRT for Women With GSM Plus Vasomotor Symptoms

Women who have both GSM and moderate-to-severe hot flashes or night sweats may benefit from systemic hormone therapy, which addresses both symptom domains simultaneously. Standard systemic options include transdermal estradiol patches (0.025 to 0.1 mg/day), estradiol gel, and estradiol spray. Women with an intact uterus require a progestogen to protect the endometrium; options include oral micronized progesterone 100 to 200 mg/day, levonorgestrel IUD, or combination patch.

The KEEPS trial (N=727 to 4 years) found that transdermal estradiol 0.045 mg/day and oral conjugated equine estrogen 0.45 mg/day both improved vaginal symptoms compared with placebo, with transdermal estradiol producing fewer adverse lipid changes [14]. For women who initiate systemic HRT primarily for vasomotor symptoms, GSM improvement typically lags by 4 to 8 weeks and may require supplemental local estradiol for the first 3 months if dyspareunia is the chief complaint.

The "timing hypothesis," supported by the WHI re-analysis and the ELITE trial, suggests that women who start estrogen therapy within 6 years of menopause onset have a more favorable cardiovascular risk profile than women who start 10 or more years after their final period [15]. This has reshaped prescribing guidance: ACOG and The Menopause Society both recommend that clinicians individualize therapy rather than apply population-level age cutoffs.

GSM and Recurrent UTIs: A Frequently Missed Connection

Genitourinary syndrome of menopause is a recognized risk factor for recurrent urinary tract infections (rUTIs), defined as two or more culture-confirmed UTIs in 6 months. The mechanism is pH-driven: a vaginal pH above 5.0 reduces Lactobacillus colonization, allowing E. coli and other uropathogens to thrive in the periurethral zone.

A randomized trial published in the New England Journal of Medicine (N=93) compared vaginal estriol cream with oral trimethoprim-sulfamethoxazole prophylaxis for rUTIs over 36 weeks. Vaginal estriol reduced the UTI incidence rate to 0.5 per patient-year versus 2.9 per patient-year at baseline. The antibiotic arm reduced incidence to 0.4 per patient-year but at the cost of resistance selection [16]. Local vaginal estrogen is now listed as a preferred option for rUTI prevention in postmenopausal women in the ACOG Practice Bulletin on UTIs [6].

Clinicians at HealthRX apply a three-step GSM assessment at every perimenopausal intake: (1) vaginal pH strip measurement, (2) a four-question Most Bothersome Symptom screen covering dryness, burning, dyspareunia, and urinary urgency, and (3) a urine dipstick to exclude active infection before attributing urinary symptoms to GSM alone. This sequence consistently identifies women who were managing dyspareunia in silence and had been attributed recurrent UTIs to bacterial causes without addressing the underlying atrophy.

Managing Hot Flashes Alongside GSM

About 80% of perimenopausal women experience vasomotor symptoms (VMS), and for many, those symptoms co-exist with GSM [17]. Hot flashes are brief, recurring sensations of intense heat caused by the narrowing of the thermoregulatory neutral zone in the hypothalamus as estrogen falls. Night sweats are the nocturnal equivalent and are a primary driver of menopause insomnia, which in turn disrupts cortisol rhythms and can worsen mood and sexual function.

For women with both VMS and GSM who are appropriate candidates for systemic therapy, transdermal estradiol at 0.05 mg/day reduces hot flash frequency by approximately 75% within 4 weeks, based on pooled data from three randomized trials (total N=1,243) [18]. Non-hormonal options for VMS include fezolinetant (Veozah, 45 mg oral daily), an FDA-approved neurokinin 3 receptor antagonist that reduced moderate-to-severe hot flash frequency by 59% in the SKYLIGHT 1 trial (N=501) at 12 weeks [19]. Fezolinetant does not address GSM; women choosing it for VMS may still need local vaginal therapy.

Venlafaxine 37.5 to 75 mg/day and paroxetine 7.5 mg/day (Brisdelle, the only SSRI/SNRI FDA-approved for VMS) reduce hot flash frequency by 40 to 60% but similarly have no effect on vaginal atrophy or urinary symptoms [20].

Addressing Menopause Insomnia in the Context of GSM

Sleep disruption affects 40 to 60% of perimenopausal and postmenopausal women. Night sweats fragment sleep architecture, but GSM also disturbs sleep directly. Nocturia from urinary urgency linked to urogenital atrophy can interrupt sleep two to four times per night. Women often attribute all nighttime awakenings to hot flashes when urethral irritation is an equal or greater contributor.

Treating GSM reduces nocturia in women with co-occurring urinary atrophy. A secondary analysis of the REJOICE trial found that women randomized to the 10-mcg estradiol insert reported a 38% reduction in nocturia episodes versus 11% in the placebo group at 12 weeks (P<0.001) [8]. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line for sleep-maintenance insomnia regardless of menopausal status, per the American Academy of Sleep Medicine, and works additively with GSM treatment when both are addressed concurrently.

Low-dose doxepin 3 to 6 mg (Silenor) is FDA-approved for sleep-maintenance insomnia and does not worsen GSM. Melatonin at 0.5 to 1 mg taken 2 hours before bed may improve sleep onset but has minimal effect on sleep maintenance in perimenopausal women based on a 2022 meta-analysis of seven trials (N=843) [21].

Starting Treatment: Practical Steps

Getting started with GSM therapy does not require a gynecology referral in most cases. Primary care providers and telehealth clinicians can prescribe local estradiol after a brief history and symptom screen. Key decision points include:

Women with an intact uterus using only vaginal estradiol at approved doses do not need progestogen co-administration, per the 2023 Menopause Society guidelines [3]. The endometrial safety data for 10-mcg vaginal estradiol inserts extend to 52 weeks without endometrial proliferation.

Women with estrogen-sensitive breast cancer should discuss local vaginal estrogen use with their oncologist. The American Cancer Society and several oncology guidelines acknowledge that local vaginal estrogen at low doses may be considered when quality-of-life impairment from GSM is severe, particularly in patients on aromatase inhibitors where systemic absorption must be monitored.

Women who prefer to start non-hormonally can begin hyaluronic acid moisturizer three times weekly and a silicone-based lubricant for intercourse while completing a shared decision-making conversation about prescription options.

Most women notice meaningful improvement in vaginal lubrication and reduced dyspareunia within 8 to 12 weeks of consistent local estradiol use. Vaginal pH typically normalizes within 6 to 8 weeks. If no response occurs by week 12, re-evaluation for alternative diagnoses, including lichen sclerosus, contact dermatitis, or pelvic floor dysfunction, is appropriate.